We are live on ! Find out more
ATYR

aTyr Pharma

50 hedge funds and large institutions have $55.8M invested in aTyr Pharma in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 16

0% more funds holding

Funds holding: 5050 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

61% less capital invested

Capital invested by funds: $143M → $55.8M (-$86.8M)

Holders
50
Holders Change
Holders Change %
0%
% of All Funds
1.33%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
8
Increased
17
Reduced
16
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SFM
51
Sphera Funds Management
Israel
-$358K -2,604 Closed
Citadel Advisors
52
Citadel Advisors
Florida
-$195K -1,421 Closed
Millennium Management
53
Millennium Management
New York
-$164K -1,192 Closed
D.E. Shaw & Co
54
D.E. Shaw & Co
New York
-$145K -1,055 Closed
NI
55
Numeric Investors
Massachusetts
-$122K -890 Closed
PCM
56
Prelude Capital Management
New York
-$46K -331 Closed
Bank of America
57
Bank of America
North Carolina
-$39K -282 Closed
Barclays
58
Barclays
United Kingdom
-$1.6K -21 -64%

ATYR Hedge Fund Activity: Q1 2016 in Review

50 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2016, worth a combined $55.8M — down 61% from $143M a quarter earlier.

Fund positioning in ATYR was balanced in Q1 2016: 8 funds opened new positions, 8 closed out, 17 added to existing stakes and 16 trimmed.

The largest buyer was Gruss Capital Management, opening a new position worth an estimated $3.26M. The largest seller was EcoR1 Capital, cutting an estimated $3.88M.

  • 50 institutional investors held aTyr Pharma (ATYR) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $55.8M of aTyr Pharma stock for Q1 2016, down 61% quarter-over-quarter.
  • 8 funds opened new aTyr Pharma positions in Q1 2016 and 8 closed out, a net change of 0 holders.
  • The largest aTyr Pharma buyer in Q1 2016 was Gruss Capital Management, an estimated $3.26M added.
  • The largest aTyr Pharma seller in Q1 2016 was EcoR1 Capital, an estimated $3.88M sold.

Based on aggregated 13F filings for Q1 2016.